Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775612 |
Pain-Sleep in Rheumatic Disease |
NOT_YET_RECRUITING | NA |
| NCT07716488 |
Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders |
RECRUITING | NA |
| NCT07504887 |
Effects of Aerobic Exercise in Rheumatoid Arthritis |
RECRUITING | NA |
| NCT07148414 |
A Study of SPY072 in Rheumatic Disease |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07101978 |
Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain |
NOT_YET_RECRUITING | NA |
| NCT00024479 |
Studies of the Natural History of Rheumatic Diseases |
RECRUITING |
